Literature DB >> 22247700

Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways.

Lu Zhou1, Emanuela Ercolano, Sylwia Ammoun, M Caroline Schmid, Magdalena A Barczyk, Clemens Oliver Hanemann.   

Abstract

Neurofibromatosis type 2 (NF2) is an inherited predisposition cancer syndrome characterized by the development of multiple benign tumors in the nervous system including schwannomas, meningiomas, and ependymomas. Using a disease model comprising primary human schwannoma cells, we previously demonstrated that adherens junctions (AJs) are impaired in schwannoma cells because of a ubiquitous, upregulated Rac activity. However, the mechanism by which loss of contact inhibition leads to proliferation remains obscure in merlin-deficient tumors. In this study, we show that proliferative Wnt/β-catenin signaling is elevated as active β-catenin (dephosphorylated at serine 37 and threoine 41) localizes to the nucleus and the Wnt targets genes c-myc and cyclin D1 are upregulated in confluent human schwannoma cells. We demonstrate that Rac effector p21-activated kinase 2 (PAK2) is essential for the activation of Wnt/β-catenin signaling because depletion of PAK2 suppressed active β-catenin, c-myc, and cyclin D1. Most importantly, the link between the loss of the AJ complex and the increased proliferation in human schwannoma cells is connected by Src and platelet-derived growth factor receptor-induced tyrosine 654 phosphorylation on β-catenin and associated with degradation of N-cadherin. We also demonstrate that active merlin maintains β-catenin and N-cadherin complex at the plasma membrane through direct regulation. Finally, we demonstrate that phosphorylation of tyrosine 654 is critical for the increased proliferation in human schwannoma cells because overexpression of a Y654F mutant β-catenin reduces hyperproliferation of schwannoma cells. We suggest a model that these pathways are coordinated and relevant for proliferation in merlin-deficient tumors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22247700      PMCID: PMC3257450          DOI: 10.1593/neo.111060

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  42 in total

1.  Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex.

Authors:  Yasuyuki Fujita; Gerd Krause; Martin Scheffner; Dietmar Zechner; Hugo E Molina Leddy; Jürgen Behrens; Thomas Sommer; Walter Birchmeier
Journal:  Nat Cell Biol       Date:  2002-03       Impact factor: 28.824

2.  Regulation of E-cadherin/Catenin association by tyrosine phosphorylation.

Authors:  S Roura; S Miravet; J Piedra; A García de Herreros; M Duñach
Journal:  J Biol Chem       Date:  1999-12-17       Impact factor: 5.157

3.  Mechanisms of VE-cadherin processing and degradation in microvascular endothelial cells.

Authors:  Kanyan Xiao; David F Allison; Margaret D Kottke; Susan Summers; George P Sorescu; Victor Faundez; Andrew P Kowalczyk
Journal:  J Biol Chem       Date:  2003-03-06       Impact factor: 5.157

4.  The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44.

Authors:  H Morrison; L S Sherman; J Legg; F Banine; C Isacke; C A Haipek; D H Gutmann; H Ponta; P Herrlich
Journal:  Genes Dev       Date:  2001-04-15       Impact factor: 11.361

Review 5.  Wnt/beta-catenin signaling.

Authors:  T Akiyama
Journal:  Cytokine Growth Factor Rev       Date:  2000-12       Impact factor: 7.638

6.  The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin.

Authors:  A H Huber; W I Weis
Journal:  Cell       Date:  2001-05-04       Impact factor: 41.582

7.  Wnt signaling controls the phosphorylation status of beta-catenin.

Authors:  Mascha van Noort; Jan Meeldijk; Ruurd van der Zee; Olivier Destree; Hans Clevers
Journal:  J Biol Chem       Date:  2002-02-07       Impact factor: 5.157

8.  NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions.

Authors:  Dominique Lallemand; Marcello Curto; Ichiko Saotome; Marco Giovannini; Andrea I McClatchey
Journal:  Genes Dev       Date:  2003-04-14       Impact factor: 11.361

9.  Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells.

Authors:  Katherine Kaempchen; Kirsten Mielke; Tamara Utermark; Sonja Langmesser; C Oliver Hanemann
Journal:  Hum Mol Genet       Date:  2003-06-01       Impact factor: 6.150

10.  Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology.

Authors:  Cristina Fernandez-Valle; Yong Tang; Jerome Ricard; Alma Rodenas-Ruano; Anna Taylor; Elizabeth Hackler; John Biggerstaff; Jared Iacovelli
Journal:  Nat Genet       Date:  2002-07-15       Impact factor: 38.330

View more
  39 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

2.  Merlin/NF2 Suppresses Pancreatic Tumor Growth and Metastasis by Attenuating the FOXM1-Mediated Wnt/β-Catenin Signaling.

Authors:  Ming Quan; Jiujie Cui; Tian Xia; Zhiliang Jia; Dacheng Xie; Daoyan Wei; Suyun Huang; Qian Huang; Shaojiang Zheng; Keping Xie
Journal:  Cancer Res       Date:  2015-10-19       Impact factor: 12.701

3.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

4.  CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.

Authors:  Brigitte C Widemann; Maria T Acosta; Sylvia Ammoun; Allan J Belzberg; Andre Bernards; Jaishri Blakeley; Antony Bretscher; Karen Cichowski; D Wade Clapp; Eva Dombi; Gareth D Evans; Rosalie Ferner; Cristina Fernandez-Valle; Michael J Fisher; Marco Giovannini; David H Gutmann; C Oliver Hanemann; Robert Hennigan; Susan Huson; David Ingram; Joe Kissil; Bruce R Korf; Eric Legius; Roger J Packer; Andrea I McClatchey; Frank McCormick; Kathryn North; Minja Pehrsson; Scott R Plotkin; Vijaya Ramesh; Nancy Ratner; Susann Schirmer; Larry Sherman; Elizabeth Schorry; David Stevenson; Douglas R Stewart; Nicole Ullrich; Annette C Bakker; Helen Morrison
Journal:  Am J Med Genet A       Date:  2014-01-17       Impact factor: 2.802

5.  Pak2 regulates myeloid-derived suppressor cell development in mice.

Authors:  Yi Zeng; Seongmin Hahn; Jessica Stokes; Emely A Hoffman; Monika Schmelz; Maria Proytcheva; Jonathan Chernoff; Emmanuel Katsanis
Journal:  Blood Adv       Date:  2017-10-10

6.  Cellular prion protein (PrPC) in the development of Merlin-deficient tumours.

Authors:  L Provenzano; Y Ryan; D A Hilton; J Lyons-Rimmer; F Dave; E A Maze; C L Adams; R Rigby-Jones; S Ammoun; C O Hanemann
Journal:  Oncogene       Date:  2017-07-10       Impact factor: 9.867

Review 7.  Development of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma.

Authors:  Jaishri Blakeley
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2012-10       Impact factor: 2.064

8.  p21-activated kinase interacts with Wnt signaling to regulate tissue polarity and gene expression.

Authors:  Kah Yee Goh; Natalie Weili Ng; Thilo Hagen; Takao Inoue
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-10       Impact factor: 11.205

9.  An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.

Authors:  Dina S Stepanova; Galina Semenova; Yin-Ming Kuo; Andrew J Andrews; Sylwia Ammoun; C Oliver Hanemann; Jonathan Chernoff
Journal:  Cancer Res       Date:  2017-07-20       Impact factor: 12.701

10.  Loss of NF2/Merlin expression in advanced sporadic colorectal cancer.

Authors:  Tamara Cačev; Gorana Aralica; Božo Lončar; Sanja Kapitanović
Journal:  Cell Oncol (Dordr)       Date:  2013-12-10       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.